SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus fueled by a series of strategic acquisitions, including the purchase of Indo Earth Moving Ltd., and a high-profile partnership with Palantir that reinforces its status as an emerging leader in autonomous defense and drone technology. The community remains heavily bullish, with traders actively debating the impact of upcoming earnings, potential government contract wins, and the stock's significant short interest as it navigates high volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is surging as investors bet on an AI-driven memory super-cycle, fueled by the company's high-volume production of HBM4 memory for Nvidia's new Vera Rubin platform and anticipation of its upcoming earnings report. The community is actively debating whether these gains are already priced in or if the stock is poised for further breakout as it prepares for inclusion in the S&P 100.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. (SWMR) is seeing intense volatility and massive retail speculation following a high-profile IPO in the drone software sector, with many traders drawing parallels to other low-float momentum plays. The community is heavily focused on the company's alleged combat-tested AI drone technology used in ongoing conflicts, fueling aggressive debates over whether the stock is a long-term defense play or an overextended pump-and-dump.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors digest news of a strategic collaboration with Samsung for HBM4 AI memory and potential foundry partnerships, while the community remains hyper-focused on how these supply chain moves position the company to compete against Nvidia. Market participants are debating whether this momentum can sustain a breakout above key technical levels, with sentiment divided between bullish expectations for long-term AI market share gains and skepticism regarding current valuations.

Aventus Network

Aventus Network (AVT) is trending as community members highlight its Polkadot integration, recent UAE-based DAO incorporation, and strategic advisory appointments as bullish catalysts for a potential breakout. Investors are actively discussing the project's low market capitalization and enterprise-grade technology while closely monitoring trading volume for signs of sustained momentum.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors weigh significant analyst downgrades and concerns over the saturation of the obesity drug market against the company's strong long-term pipeline potential and clinical leadership. The community remains deeply divided, with some traders taking short positions to capitalize on technical resistance while others treat the price dip as a buying opportunity in anticipation of upcoming oral drug approvals.

Siemens Energy AG engages in the provision of energy technology solutions. It operates through the following segments: Gas Services, Grid Technologies, Transformation of Industry, and Siemens Gamesa. The company was founded in 1866 and is headquartered in Munich, Germany.

Siemens Energy AG - ADR - Sponsored

Investors are expressing strong bullish sentiment regarding the company's substantial order backlog and potential for sustained growth, often characterizing the stock as a reliable long-term holding.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing intense trading activity as investors bet on a persistent multi-year memory shortage and sustained AI-driven demand, fueling discussions of a potential parabolic run or an impending rug pull. While some traders are aggressively shorting the stock, citing extreme valuations, others are focused on its correlation with memory sector leaders like Micron and anticipation surrounding upcoming industry conferences.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is seeing high trading volume and intense debate among investors as they track upcoming regulatory milestones and weigh the company's pre-revenue status against its long-term potential in nuclear energy. The community is actively discussing the stock's recent price volatility, insider activity, and the impact of the broader nuclear energy narrative on its future valuation.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending as investors digest a recent update showing continued recurrence rate reduction in the open-label arm of its ongoing Phase III FLAMINGO-01 trial, with community sentiment bolstered by the involvement of a prestigious, co-authoring Steering Committee. The stock remains a focal point for biotech discussions due to its lean operation, significant insider accumulation, and anticipation of upcoming AACR abstract releases, which many speculate will provide further validation of the drug's clinical potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The patient had a tumor shrinkage of 50% and notable decline in the tumor biomarker CA-125, the company said.&nbsp;</li><li>The patient experienced only low-grade treatment-emergent adverse effects and continued treatment.</li><li>The company is now eyeing confirmation of the partial response observed in both its patients in subsequent imaging assessments.</li></ul>Shares of Aprea Therapeutics, Inc. (APRE) rallied 15% on Wednesday after the company said that it observed tumor shrinkage in a patient enrolled in an early-stage trial of its experimental drug APR-1051.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-additional-positive-clinical">reported</a> a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level. The patient had a tumor shrinkage of 50% and notable decline in the tumor biomarker CA-125, the company said.The patient experienced only low-grade treatment-emergent adverse effects and continued treatment, Aprea said. The first patient to achieve a partial response at 150 mg dose levels also remains on therapy as the experimental oral therapy is generally well-tolerated, the company added.<h2 class="st-heading-2">Steps Ahead</h2>The company is now eyeing confirmation of the partial response observed in both its patients in subsequent imaging assessments. Further updates from the trial are expected in the second quarter of 2026. The study is aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of APR-1051 in patients with advanced solid tumors and nearly 22 patients have been treated at varying doses of 10mg to 220 mg.“We believe the magnitude of tumor reduction and the substantial drop in CA-125 in this patient provides further evidence of APR-1051’s biologic activity and potential therapeutic impact,” said Eugene Kennedy, Chief Medical Advisor at Aprea.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around APRE stock increased from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume improved from ‘extremely low’ to ‘normal’ levels.According to data from Koyfin, all the three analysts covering the stock rate it ‘Buy’ or higher. The 12-month average price target on the stock is at $5.33, representing a potential upside of about 788% from last day’s closing price.<a href="https://stocktwits.com/symbol/APRE">APRE stock</a> has declined 80% over the past 12 months.&nbsp;Read More: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy">SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aprea Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.

Equity

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.


Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars

Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.read more...

New Strong Sell Stocks for January 19th

APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.

 New Strong Sell Stocks for Jan. 14

APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

Marc Duey Acquires 21,459 Shares of Aprea Therapeutics (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey purchased 21,459 shares of the firm's stock in a transaction on Wednesday, December 10th. The shares were acquired at an...

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

APRE
Aprea Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest APRE News

APREAprea Therapeutics Inc